Cardiac Science Announces Third Quart...(% of % of ...),Health

Date:11/9/2009

% of % of revenue revenue ----------------------------------- Net income (loss) attributable to Cardiac Science Corporation $(66,546) -171.1% $2,478 4.6% Depreciation and amortization 1,595 4.1% 1,544 2.9% Interest income (23) -0.1% (156) -0.3% Income tax expense 43,923 113.0% 1,598 3.0% ------ ----- ----- --- EBITDA (21,051) -54.1% 5,464 10.1% Stock-based compensation 674 1.7% 469 0.9% AED field initiative 18,500 n/m - n/m Adjusted EBITDA $(1,877) -4.8% $5,933 11.0% ======= ==== ====== ==== Reconciliation of Net Income (Loss) Attributable to Cardiac Science Corporation to Adjusted EBITDA Nine Months Nine Months Ended Ended September 30, September 30, 2009 2008 ------------------------------------- % of % of revenue revenue ------------------------------------- Net income (loss) attributable to Cardiac Science Corporation
'/>"/>

SOURCE Cardiac Science Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Related medicine technology :

1. Personalized Medicine - The Genomic Revolution in Cardiac Care
2. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
3. Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor
4. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
5. Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
6. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
7. Do-It-Yourself Cardiac Bypass Surgery: All You Need is Walking Shoes
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
10. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
11. Study Finds PCI Safe, Effective Despite Off-Site Cardiac Surgery